Evolution and clinical translation of drug delivery nanomaterials
- Evolution and clinical translation of drug delivery nanomaterials
- 서정목; Shabir Hassan; Gyan Prakash; Ayca Bal Ozturk; Saghi Saghazadeh; Muhammad Farhan Sohail; Mehmet Remzi Dokmeci; Yu Shrike Zhang; Ali Khademhosseini
- Drug delivery; Inorganic nanomaterial; Polymeric nanomaterial; Liposomes; Clinical trials; FDA approval
- Issue Date
- NANO TODAY
- VOL 15-106
- With the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterialbased drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rate and bio-distribution still exist, thus making their successful translation to clinical application very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review, the stress has been made on the evolution of nanomaterials that are under different stages of clinical trials or have been approved by the United States Food and Drug Administration (FDA).
- Appears in Collections:
- KIST Publication > Article
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.